SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
Under the Securities Exchange Act of 1934
SCHEDULE 13G
INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SIGA Technologies, Inc.
-----------------------
(Name of Issuer)
Common Stock, par value $.0001 per share
----------------------------------------
(Title of Class of Securities)
826917-10-6
-----------
(CUSIP Number)
May 23, 2003
------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
-------
Page 1 of 6 Pages
SCHEDULE 13G
CUSIP No. 826917-10-6 Page 2 of 6 Pages
------------------------------------------------------------------------------
1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Plexus Vaccine Inc.
-------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_|
(b) |X|
-------------------------------------------------------------------------------
3) SEC USE ONLY
-------------------------------------------------------------------------------
4) CITIZENSHIP OR PLACE OF ORGANIZATION
CA
-------------------------------------------------------------------------------
5) SOLE VOTING POWER
NUMBER 1,950,000
OR --------------------------------------------------------
SHARES 6) SHARED VOTING POWER
BENEFICIALLY
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7) SOLE DISPOSITIVE POWER
PERSON
WITH 1,950,000
--------------------------------------------------------
8) SHARED DISPOSITIVE POWER
None
-------------------------------------------------------------------------------
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,950,000
-------------------------------------------------------------------------------
10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|-|
-------------------------------------------------------------------------------
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.72%
-------------------------------------------------------------------------------
12) TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
2
Schedule 13G
------------
Item 1(a). Name of Issuer:
SIGA Technologies, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
420 Lexington Avenue
Suite 601
New York, NY 10170
Item 2(a). Name of Person Filing:
Plexus Vaccine Inc.
Item 2(b). Address of Principal Business Office or, if None, Residence:
11770 Bernardo Plaza Court, Suite 375
San Diego, CA 92128
Item 2(c). Citizenship:
CA
Item 2(d). Title of Class of Securities:
Common Stock, par value $.0001 per share
Item 2(e). CUSIP Number:
82 6917-10-6
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b), or
240.13d-2(b) or (c), check whether the person filing is a:
(a) |_| Broker or Dealer Registered Under Section 15 of the Act (15
U.S.C. 78o)
(b) |_| Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
(c) |_| Insurance Company as defined in section 3(a)(19) of the Act (15
U.S.C. 78c)
3
(d) |_| Investment Company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8)
(e) |_| Investment Adviser in accordance with ss.240.13d-1(b)(1)(ii)(E)
(f) |_| Employee benefit plan or endowment fund in accordance with
ss.240.13d-1(b)(1)(ii)(F)
(g) |_| Parent Holding Company or control person in accordance with
ss.240.13d-1(b)(ii)(G)
(h) |_| Savings Association as defined in ss.3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813)
(i) |_| Church plan that is excluded from the definition of an
investment company under ss.3(c)(15) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3)
(j) |_| Group, in accordance with ss.240.13d-1(b)(ii)(J)
Item 4. Ownership.
(a) Amount beneficially owned: 1,950,000
(b) Percent of class: 14.72%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 1,950,000
(ii) Shared power to vote or to direct the vote: None
(iii) Sole power to dispose or to direct the disposition of:
1,950,000
(iv) Shared power to dispose or to direct the disposition of:
None
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following: |_|
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
4
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purposes or effect.
SIGNATURE
---------
After reasonable inquiry and to the best knowledge and belief of the
undersigned, the undersigned certifies that the information set forth in this
Statement is true, complete and correct.
May 28, 2003
------------------------
Date
PLEXUS VACCINE INC.
By: /s/ Susan K. Burgess
----------------------------
Name: Susan K. Burgess
Title: President and Chief
Executive Officer
5